EGFR and non-small cell lung carcinoma: Although immune checkpoint blockade (ICI) has been successfully utilized in treating patients with non-small cell lung cancer (NSCLC), the benefit of ICI for patients with advanced EGFR-mutant NSCLC has been limited.